Antibody improves progression-free survival in patients with advanced prostate cancer – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Sep 29 2020
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasized, castration-resistant prostate cancer.
This is the finding of the long-term analyses of an international phase 3 clinical trial, recently published in the leading journal “European Urology”. The study showed that overall survival was 2 – 3 times higher than in the placebo arm.
Ipilimumab is a humanized monoclonal IgG1 antibody that is…

Click here to view the original article.